ArticleThe Kaohsiung journal of medical sciences2026
Identification of Clinical Factors Associated With the Immunogenicity of Homologous ChAdOx1-nCoV-19 Vaccine in Hemodialysis Patients.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hemodialysis (HD) patients are at higher risk of severe COVID-19 and may exhibit suboptimal vaccine responses. This study evaluates the factors influencing vaccine-induced immunity in HD patients following the second dose of the Vaxzevria. A total of 276 HD patients and 126 controls were included. Antibody responses were assessed using binding antibody units (BAU). Operational antibody thresholds used in prior literature were applied to classify antibody levels as evaluated as 50% and 60% vaccine efficacy (VE) levels after the first dose and second dose separately. Linear regression model and stratification by baseline characteristics were performed to identify clinical factors associated with vaccine responses. HD patients had significantly lower median antibody levels compared to healthy subjects. Antibody levels decreased with age, with the oldest tertile having the lowest response. Higher BMI and favorable body composition, such as increased fat tissue index, were positively correlated with stronger immune responses. Patients with elderly, diabetes mellitus, heart failure, and low BMI were associated with reduced antibody responses and lower rates of achieving 50% and 60% VE thresholds. Vaccine-induced immunity in HD patients is influenced by age, BMI, body composition, and comorbidities. Tailored vaccination strategies, including booster doses, are essential to enhance protection in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.